论文部分内容阅读
目的:观察前列地尔联合缬沙坦治疗早期糖尿病肾病的疗效。方法:选择我院2014年1月—2016年4月收治的早期糖尿病肾病患者50例,按照数字随机方式将全部患者分为对照组和联合治疗组,对照组患者采用前列地尔治疗,联合治疗组患者则采用前列地尔联合缬沙坦治疗。结果:经1个疗程的治疗,联合治疗组患者的临床治疗总有效率显著高于对照组患者(P<0.05);两组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论:临床中在对早期糖尿病肾病患者进行治疗时,前列地尔联合缬沙坦治疗具有比较显著的临床疗效,安全可靠,具有临床推广价值。
Objective: To observe the efficacy of alprostadil combined with valsartan in the treatment of early diabetic nephropathy. Methods: Fifty patients with early diabetic nephropathy admitted from January 2014 to April 2016 in our hospital were randomly divided into control group and combination therapy group. Patients in the control group were treated with alprostadil and combination therapy Group patients were treated with alprostadil plus valsartan. Results: After one course of treatment, the total effective rate of clinical treatment in the combined treatment group was significantly higher than that in the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05) . Conclusion: In the clinical treatment of patients with early diabetic nephropathy, alprostadil combined with valsartan has a significant clinical efficacy, safety and reliability, and has clinical value of promotion.